PACAP38 increases vesicular monoamine transporter 2 (VMAT2) expression and attenuates methamphetamine toxicity
Authors:
- J.R. RichardsonJRJ.R. Richardson
- M.Z. WangMWM.Z. Wang
- Y.J. LiYLY.J. Li
- G.W. MillerGMG.W. Miller
- 1 August 2008
- journal article
- Published by Elsevier in Neuropeptides
- Vol. 42 (4) , 423-434
Abstract
No abstract availableKeywords
This publication has 82 references indexed in Scilit:
- The newly synthesized pool of dopamine determines the severity of methamphetamine‐induced neurotoxicityJournal of Neurochemistry, 2007
- A rapid oxidation and persistent decrease in the vesicular monoamine transporter 2 after methamphetamineJournal of Neurochemistry, 2007
- PACAP stimulates the sustained phosphorylation of tyrosine hydroxylase at serine 40Cellular Signalling, 2007
- Inflammation as a causative factor in the aetiology of Parkinson's diseaseBritish Journal of Pharmacology, 2007
- Dieldrin exposure induces oxidative damage in the mouse nigrostriatal dopamine systemExperimental Neurology, 2007
- Pituitary adenylate cyclase-activating polypeptide (PACAP) decreases ischemic neuronal cell death in association with IL-6Proceedings of the National Academy of Sciences, 2006
- PACAP—A Multifacetted NeuropeptideChronobiology International, 2006
- Microglial activation is a pharmacologically specific marker for the neurotoxic amphetaminesNeuroscience Letters, 2004
- Effects of dopaminergic drug treatments on in vivo radioligand binding to brain vesicular monoamine transportersNuclear Medicine and Biology, 1996
- Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cellsBiochemical and Biophysical Research Communications, 1989